<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109573</url>
  </required_header>
  <id_info>
    <org_study_id>R&amp;DCL1403</org_study_id>
    <nct_id>NCT04109573</nct_id>
  </id_info>
  <brief_title>Function Following Laser for Anal Intraepithelial Neoplasia (FLAN)</brief_title>
  <acronym>FLAN</acronym>
  <official_title>Function Following Laser for Anal Intraepithelial Neoplasia (FLAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Homerton University Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Homerton University Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-grade squamous intraepithelial lesions (HSIL) and anal cancer are rising in incidence
      and at highest risk are HIV positive men who have sex with men (MSM). This pilot study
      assessing anal function and patient-reported outcomes before and after laser ablation of HSIL
      will add to the evidence that such a therapy is an acceptable and safe treatment to offer in
      a preventative setting.We will be recruting HIV positive and negative MSM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High resolution anoscopy with targeted laser ablation is one of the therapies currently
      employed to treat HSIL of the anus to prevent progression to anal cancer. The functional
      outcome of this procedure has not previously been formally assessed.

      HIV and negative positive MSM in whom HSIL has been detected will form the study population,
      as HSIL is prevalent in these patients and intervention is felt to be indicated. Functional
      assessments will be carried out prior to initial treatment and then repeated six months after
      laser ablation therapy. The structure, function and sensitivity of the anal canal will be
      evaluated using endoanal ultrasound, high-resolution anal manometry and anal mucosal
      electrosensitivity measurements respectively. Patient-reported outcomes will be assessed
      using questionnaires and semi-structured interviews at baseline, 4 weeks and 6 months
      post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Manometric indices</measure>
    <time_frame>Six months</time_frame>
    <description>Changes in pressure vailues - resting pressure and maximum squeeze pressure compared to patient's own pre treatment values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anal mucosal sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in sensitivity as measured against patients own pre treatment perception</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoanal ultrasound abnormalities</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in endoanal ultrasound abnormalities compared to pre-treatment findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical and psychological well-being</measure>
    <time_frame>4 weeks 6 months</time_frame>
    <description>Qualitative subjective physical and psychological well-being 4 weeks and 6 months after procedure of laser mucosal ablation of AIN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Patient reported outcomes, particularly with regard to sexual function and bowel function</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anus Cancer</condition>
  <condition>Fecal Incontinence</condition>
  <condition>Anal Intraepithelial Neoplasia</condition>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>Anorectal function post anal laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
Device: laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high resolution anal manometry</intervention_name>
    <description>functional studies before and after anal laser ablation</description>
    <arm_group_label>Anorectal function post anal laser</arm_group_label>
    <other_name>endoanal ultrasound</other_name>
    <other_name>gastrointestinal physiology</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        MSM &gt;18 years of age if HIV positive, CD4 count of over 350; if less, been on highly active
        antiretroviral treatment for at least 3 months Histologically proven high-grade squamous
        anal intraepithelial neoplasia lesion (HSIL) Anal canal disease with or without perianal
        disease Written informed consent

        Exclusion Criteria:

        Previous laser or other ablative treatment for HSIL (previous topical treatment is not
        excluded) Any treatment for HSIL in the previous six months Previous or current diagnosis
        of anal cancer Concurrent or previous (if severe) perianal inflammatory bowel disease,
        complex fistula or other significant perianal condition requiring surgery including
        fissures, current fistula in ano and Grade III or IV haemorrhoids Perianal sepsis Perianal
        disease only without anal canal HSIL
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamzin Cuming, FRCS</last_name>
    <role>Study Director</role>
    <affiliation>Homerton University Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamzin Cuming, FRCS</last_name>
    <phone>02085105555</phone>
    <email>Tamzin.cuming@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Inwang, MSc</last_name>
    <phone>02085105134</phone>
    <email>christine.mitchell-inwang@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Homerton University Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamzin Cuming, FRCS, MBBS</last_name>
      <phone>02085105555</phone>
      <email>tamzin.cuming@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Mayura Nathan, FRCS</last_name>
      <phone>02085105555</phone>
      <phone_ext>7979</phone_ext>
      <email>mayura.nathan@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>laser ablation</keyword>
  <keyword>anal intraepithelial neoplasia</keyword>
  <keyword>AIN</keyword>
  <keyword>fecal incontinence</keyword>
  <keyword>anal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Fecal Incontinence</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

